Susceptibilities of genital mycoplasmas to the newer quinolones as determined by the agar dilution method.
about
A random sequencing approach for placing markers on the physical map of Mycoplasma genitaliumSusceptibilities of Mycoplasma hominis and Ureaplasma urealyticum to two new quinolones, sparfloxacin and WIN 57273In vitro susceptibilities of Mycoplasma pneumoniae, Mycoplasma hominis, and Ureaplasma urealyticum to sparfloxacin and PD 127391.Sparfloxacin selects gyrase mutations in first-step Mycoplasma hominis mutants, whereas ofloxacin selects topoisomerase IV mutations.Comparative in vitro susceptibilities and bactericidal activities of investigational fluoroquinolone ABT-492 and other antimicrobial agents against human mycoplasmas and ureaplasmasHematoma and abscess formation caused by Mycoplasma hominis following cesarean sectionIn vitro susceptibilities to and bactericidal activities of garenoxacin (BMS-284756) and other antimicrobial agents against human mycoplasmas and ureaplasmasIn vitro antibiotic susceptibility testing of clinical isolates of Mycoplasma penetrans from patients with AIDS.Increase in resistance of Mycoplasma hominis to tetracyclines.In vitro antimycoplasmal activities of rufloxacin and its metabolite MF 922.In vitro antibiotic susceptibility testing of different strains of Mycoplasma fermentans isolated from a variety of sourcesIn vitro susceptibility of Ureaplasma urealyticum and Mycoplasma hominis isolates in Argentina.Newly documented antimicrobial activity of quinolones.A review of the antimicrobial activity of the fluoroquinolones.The effect of ciprofloxacin and doxycycline plus metronidazole on lower genital tract flora in patients with proven pelvic inflammatory disease.In vitro susceptibilities of Mycoplasma hominis to six fluoroquinolones as determined by E test.Susceptibilities of Mycoplasma hominis, M. pneumoniae, and Ureaplasma urealyticum to GAR-936, dalfopristin, dirithromycin, evernimicin, gatifloxacin, linezolid, moxifloxacin, quinupristin-dalfopristin, and telithromycin compared to their susceptibilSusceptibilities of Mycoplasma pneumoniae, Mycoplasma hominis, and Ureaplasma urealyticum to a new quinolone, trovafloxacin (CP-99,219).Intraprostatic distribution of lomefloxacin following multiple-dose administration.Susceptibilities of Mycoplasma hominis, Mycoplasma pneumoniae, and Ureaplasma urealyticum to a new quinolone, OPC 17116.Susceptibilities of Mycoplasma hominis, Mycoplasma pneumoniae, and Ureaplasma urealyticum to new glycylcyclines in comparison with those to older tetracyclines.Susceptibility of Mycoplasma pneumoniae to several new quinolones, tetracycline, and erythromycin.Pharmacokinetics of difloxacin in olive flounder Paralichthys olivaceus at two water temperatures.Permeability and concentration of levofloxacin in epithelial lining fluid in patients with lower respiratory tract infections.Comparative in vitro activity of azithromycin, clarithromycin, erythromycin and lomefloxacin against Mycoplasma pneumoniae, Mycoplasma hominis and Ureaplasma urealyticum.Chemical constituents of Euonymus fortunei.
P2860
Q24629058-9C7D293D-A6B2-48E5-AD9C-E5A829E29280Q28333684-E18E2E50-8FD8-4D6C-BF0C-A7B4E1C40AC3Q33744065-EC1A57BF-90C2-436B-88CF-CA25EF029E59Q33977877-FD59AE2C-7BA8-47D1-81EF-D84F21DB5707Q34230978-67C3F6D8-DE78-413E-81C5-CA6171980238Q34574124-47C9259B-52A6-4C45-99C7-73728932B283Q34722677-35FB60CE-92B7-4F47-BD1D-CB38BE4C204FQ35115649-BCE4FC85-5228-4A59-AE6F-D0D9C655A98EQ35284107-4B1944F9-FE03-457A-B850-CF44E178274EQ35822578-3A02F420-FD4D-4519-A2CC-DB6963E96832Q35900393-D5401BB7-C772-4FA1-9858-87B6D35F9500Q36624949-944DD8B0-8FF3-4137-8918-557B683028D1Q37222571-6043DC29-B23C-433B-9D83-14311CEC3848Q37834318-38315805-5FC3-4452-B807-F278413EFC34Q37895549-DCD4B7FC-56AF-4D29-BAC8-92B8D6AECBDAQ39472088-71C0DDF7-304B-49BB-80C2-BDC9C2E3BDBDQ39478313-737B980D-A391-474E-B0C6-2E2204426224Q39781930-1B2A6ED3-F5ED-4FDF-9400-D25F247E0C66Q39817359-62A80E2E-E786-40E3-910A-22197BD5A8BCQ39866485-D30C7F46-1D56-4736-A915-677219603121Q39867257-0038CE99-0036-4442-9630-77B981A8DA4EQ40086180-FFB3ADF4-FD6B-4447-A55D-099C4ABC9A3AQ42602439-B993A24E-AC8D-4DBE-B7E0-37C5B4C783B7Q43207762-A8C5D850-3E40-4D7C-817C-2C1760516F99Q44040319-CBB642B2-7004-4AE0-B3A3-13B245BCDCCAQ53250459-D05ACE98-B9C6-464A-A308-E9B2DBFEBC4D
P2860
Susceptibilities of genital mycoplasmas to the newer quinolones as determined by the agar dilution method.
description
1989 nî lūn-bûn
@nan
1989 թուականի Յունուարին հրատարակուած գիտական յօդուած
@hyw
1989 թվականի հունվարին հրատարակված գիտական հոդված
@hy
1989年の論文
@ja
1989年論文
@yue
1989年論文
@zh-hant
1989年論文
@zh-hk
1989年論文
@zh-mo
1989年論文
@zh-tw
1989年论文
@wuu
name
Susceptibilities of genital my ...... d by the agar dilution method.
@ast
Susceptibilities of genital my ...... d by the agar dilution method.
@en
type
label
Susceptibilities of genital my ...... d by the agar dilution method.
@ast
Susceptibilities of genital my ...... d by the agar dilution method.
@en
prefLabel
Susceptibilities of genital my ...... d by the agar dilution method.
@ast
Susceptibilities of genital my ...... d by the agar dilution method.
@en
P2093
P2860
P356
P1476
Susceptibilities of genital my ...... d by the agar dilution method.
@en
P2093
F D Cartwright
M C Roberts
T M Hooton
P2860
P304
P356
10.1128/AAC.33.1.103
P407
P577
1989-01-01T00:00:00Z